Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ningetinib in Advanced Solid Tumors
NCT04577703Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ningetinib in solid tumor (advanced stage), sponsored by Sunshine Lake Pharma. Primary endpoint: Maximum Tolerated Dose. Started Feb 2014; status: completed.
02
Drugs
ningetinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04577703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577703.